Latest Cervarix Stories
WINSTON-SALEM, N.C., Sept.
Cervical cancer vaccines have gotten quite a boost since a United States advisory panel recommended the approval of GlaxoSmithKline's Cervarix, which is expected to give Merck & Co's Gardasil a run for its money.
NEW YORK, Sept.
PHILADELPHIA, Sept. 9 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S.
Researchers have found that the popular and highly advertised cervical cancer vaccine Gardasil has a low rate of side effects, but 32 deaths and questionable promotion strategies by its maker Merck & Co has raised some concern.
The World Health Organization (WHO) has now approved a new cervical cancer vaccine from pharmaceutical company GlaxoSmithKline.
LONDON, July 7 /PRNewswire/ -- The final analysis of the largest efficacy trial of a cervical cancer vaccine is published today in The Lancet.
Even under favorable assumptions, including lifelong protection against 70% of all cervical cancers and no side effects, vaccination against the human papillomavirus (HPV) is not cost-effective in the Netherlands, according to a study published online July 1 in the Journal of the National Cancer Institute.
The HPV vaccine isnâ€™t just for teens. New research shows women ages 24 to 45 not already infected with the common sexually transmitted disease can receive protection against the virus following vaccination.
Informing men that a new vaccine to prevent human papillomavirus (HPV) would also help protect their female partners against developing cervical cancer from the sexually transmitted infection did not increase their interest in getting the vaccine, according to a new Florida State University study.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.